Dashboard
1
Poor Management Efficiency with a low ROCE of 35.57%
- The company has been able to generate a Return on Capital Employed (avg) of 35.57% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 8.21% and Operating profit at -16.14% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 4.92%, it has a fair valuation with a 1.76 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
32.58%
0%
32.58%
6 Months
9.2%
0%
9.2%
1 Year
6.65%
0%
6.65%
2 Years
41.77%
0%
41.77%
3 Years
-10.84%
0%
-10.84%
4 Years
-40.32%
0%
-40.32%
5 Years
-68.67%
0%
-68.67%
Qingdao Haier Biomedical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.21%
EBIT Growth (5y)
-16.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
0.51
Tax Ratio
2.26%
Dividend Payout Ratio
41.25%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.76%
ROE (avg)
14.04%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.76
EV to EBIT
47.75
EV to EBITDA
28.03
EV to Capital Employed
2.06
EV to Sales
2.85
PEG Ratio
NA
Dividend Yield
1.34%
ROCE (Latest)
4.31%
ROE (Latest)
4.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
644.40
652.10
-1.18%
Operating Profit (PBDIT) excl Other Income
90.00
98.90
-9.00%
Interest
0.90
0.90
Exceptional Items
1.70
0.50
240.00%
Consolidate Net Profit
68.90
80.00
-13.88%
Operating Profit Margin (Excl OI)
89.30%
101.80%
-1.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -1.18% vs 14.91% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -13.88% vs 50.94% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,315.80
2,269.50
2.04%
Operating Profit (PBDIT) excl Other Income
301.80
404.30
-25.35%
Interest
7.10
4.90
44.90%
Exceptional Items
-0.30
7.10
-104.23%
Consolidate Net Profit
255.10
381.00
-33.04%
Operating Profit Margin (Excl OI)
75.10%
124.20%
-4.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.04% vs 0.12% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -33.04% vs -7.55% in Dec 2024
About Qingdao Haier Biomedical Co., Ltd. 
Qingdao Haier Biomedical Co., Ltd.
Industrial Manufacturing
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






